DNLI
Price
$15.27
Change
-$0.38 (-2.43%)
Updated
Aug 29 closing price
Capitalization
2.23B
61 days until earnings call
XENE
Price
$38.71
Change
+$0.11 (+0.28%)
Updated
Aug 29 closing price
Capitalization
2.98B
67 days until earnings call
Interact to see
Advertisement

DNLI vs XENE

Header iconDNLI vs XENE Comparison
Open Charts DNLI vs XENEBanner chart's image
Denali Therapeutics
Price$15.27
Change-$0.38 (-2.43%)
Volume$1.89M
Capitalization2.23B
Xenon Pharmaceuticals
Price$38.71
Change+$0.11 (+0.28%)
Volume$677.58K
Capitalization2.98B
DNLI vs XENE Comparison Chart in %
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. XENE commentary
Aug 31, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Hold and XENE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 31, 2025
Stock price -- (DNLI: $15.27 vs. XENE: $38.71)
Brand notoriety: DNLI and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 118% vs. XENE: 59%
Market capitalization -- DNLI: $2.23B vs. XENE: $2.98B
DNLI [@Biotechnology] is valued at $2.23B. XENE’s [@Biotechnology] market capitalization is $2.98B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.25B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileXENE’s FA Score has 1 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, XENE is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 5 TA indicator(s) are bullish while XENE’s TA Score has 6 bullish TA indicator(s).

  • DNLI’s TA Score: 5 bullish, 4 bearish.
  • XENE’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, XENE is a better buy in the short-term than DNLI.

Price Growth

DNLI (@Biotechnology) experienced а -1.42% price change this week, while XENE (@Biotechnology) price change was -0.33% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.70%. For the same industry, the average monthly price growth was +20.57%, and the average quarterly price growth was +29.45%.

Reported Earning Dates

DNLI is expected to report earnings on Oct 30, 2025.

XENE is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (-0.70% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XENE($2.99B) has a higher market cap than DNLI($2.23B). XENE YTD gains are higher at: -1.250 vs. DNLI (-25.074). XENE has higher annual earnings (EBITDA): -315.5M vs. DNLI (-521.52M). DNLI has more cash in the bank: 899M vs. XENE (488M). XENE has less debt than DNLI: XENE (8.72M) vs DNLI (46.6M). XENE has higher revenues than DNLI: XENE (7.5M) vs DNLI (0).
DNLIXENEDNLI / XENE
Capitalization2.23B2.99B75%
EBITDA-521.52M-315.5M165%
Gain YTD-25.074-1.2502,006%
P/E RatioN/AN/A-
Revenue07.5M-
Total Cash899M488M184%
Total Debt46.6M8.72M535%
FUNDAMENTALS RATINGS
DNLI vs XENE: Fundamental Ratings
DNLI
XENE
OUTLOOK RATING
1..100
1123
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
75
Overvalued
PROFIT vs RISK RATING
1..100
10037
SMR RATING
1..100
9696
PRICE GROWTH RATING
1..100
5242
P/E GROWTH RATING
1..100
996
SEASONALITY SCORE
1..100
1850

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XENE's Valuation (75) in the Biotechnology industry is in the same range as DNLI (93). This means that XENE’s stock grew similarly to DNLI’s over the last 12 months.

XENE's Profit vs Risk Rating (37) in the Biotechnology industry is somewhat better than the same rating for DNLI (100). This means that XENE’s stock grew somewhat faster than DNLI’s over the last 12 months.

XENE's SMR Rating (96) in the Biotechnology industry is in the same range as DNLI (96). This means that XENE’s stock grew similarly to DNLI’s over the last 12 months.

XENE's Price Growth Rating (42) in the Biotechnology industry is in the same range as DNLI (52). This means that XENE’s stock grew similarly to DNLI’s over the last 12 months.

XENE's P/E Growth Rating (6) in the Biotechnology industry is significantly better than the same rating for DNLI (99). This means that XENE’s stock grew significantly faster than DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIXENE
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
74%
Momentum
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
75%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 4 days ago
72%
Declines
ODDS (%)
Bearish Trend 11 days ago
80%
Bearish Trend 12 days ago
74%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
78%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PJGCX14.58N/A
N/A
PGIM Jennison Focused Value C
BOSYX20.23N/A
N/A
BNY Mellon Sm Cp Val Y
OGICX39.92N/A
N/A
Invesco Global Opportunities C
GTTUX59.18N/A
N/A
Goldman Sachs Small Cp Val Insghts R6
FLCPX25.90N/A
N/A
Fidelity SAI US Large Cap Index

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with NRIX. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-2.43%
NRIX - DNLI
58%
Loosely correlated
-0.74%
BEAM - DNLI
58%
Loosely correlated
-2.91%
ARWR - DNLI
57%
Loosely correlated
-1.39%
OCUL - DNLI
54%
Loosely correlated
-2.48%
RGNX - DNLI
53%
Loosely correlated
-0.89%
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with IDYA. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
+0.28%
IDYA - XENE
59%
Loosely correlated
-1.52%
CRNX - XENE
55%
Loosely correlated
+1.11%
ATXS - XENE
52%
Loosely correlated
-5.36%
NRIX - XENE
52%
Loosely correlated
-0.74%
OCUL - XENE
50%
Loosely correlated
-2.48%
More